MMP-3 -1171 5A/6A promoter polymorphism and cancer susceptibility: an updated meta-analysis and trial sequential analysis.

Purpose: Previous studies of MMP-3 -1171 5A/6A in cancers have produced inconclusive outcomes. This updated meta-analysis was performed to clarify the link between this variant and cancer. Methods: Databases including PubMed, Google Scholar, EMBASE and Cochrane were searched for data collection. The associations were calculated by odds ratios with 95% CIs. Results: 63 eligible studies with 14,252 cases and 15,176 controls were included. The codominant 2, codominant 3, dominant, recessive and allele models were found to be significantly associated with 1.28-, 1.13-, 1.13-, 1.19- and 1.13-fold enhanced overall risk of cancer, respectively. Stratification analysis revealed a 1.28-times enhanced risk of esophageal cancer (codominant 1), 1.29- and 1.26-fold (codominant 3) and 1.18- and 1.28-fold (recessive model) enhanced risk in colorectal and gastrointestinal cancers, respectively, 1.30-, 1.35- and 1.22-times in codominant model 1, dominant and allele models for breast cancer, 1.56-fold (codominant 2) for gynecological cancer and 2.40-times in codominant model 2 for hepatocellular cancer. Conclusion: This meta-analysis suggests a significant association between the MMP-3 -1171 5A/6A variant and cancer. This meta-analysis was registered at INPLASY (registration number: INPLASY202280049).

[1]  Mohammad Safiqul Islam,et al.  Effect of miR-196a2 rs11614913 Polymorphism on Cancer Susceptibility: Evidence From an Updated Meta-Analysis , 2022, Technology in cancer research & treatment.

[2]  J. Dai,et al.  Matrix Metalloproteinase 3: A Promoting and Destabilizing Factor in the Pathogenesis of Disease and Cell Differentiation , 2021, Frontiers in Physiology.

[3]  F. Bray,et al.  The ever‐increasing importance of cancer as a leading cause of premature death worldwide , 2021, Cancer.

[4]  Mohammad Safiqul Islam,et al.  Human TERT promoter polymorphism rs2853669 is associated with cancers: an updated meta-analysis , 2021, Human Cell.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[7]  Sarah Jafrin,et al.  Association study of IL10 gene polymorphisms (rs1800872 and rs1800896) with cervical cancer in the Bangladeshi women. , 2020, International immunopharmacology.

[8]  A. Jakubowska,et al.  Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population , 2020, Hereditary Cancer in Clinical Practice.

[9]  M. Moses,et al.  Metalloproteinases and their roles in human cancer , 2020, Anatomical record.

[10]  Medhat A. Haroun,et al.  Association of matrix metalloproteinases 3 and 9 single nucleotide polymorphisms with breast cancer risk: A case-control study. , 2020, Molecular and clinical oncology.

[11]  R. Rosli,et al.  Matrix Metallopeptidase 3 Polymorphisms: Emerging genetic Markers in Human Breast Cancer Metastasis , 2020, Journal of breast cancer.

[12]  Xianling Cong,et al.  Association Between Matrix Metalloproteinase-1, 2, 3 Polymorphisms and Oral Cancer Risk: A Meta-Analysis. , 2018, Genetic testing and molecular biomarkers.

[13]  Amal M. H. Mackawy,et al.  Significance of matrix metalloproteinase-1 and -3 gene polymorphisms and their expression in normal and neoplastic endometrium , 2017 .

[14]  R. K. Galimudi,et al.  Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer , 2017, PloS one.

[15]  F. A. Bayoumi,et al.  Gene Polymorphism of Matrix Metalloproteinases 3, and 9 in Breast Cancer , 2016, The FASEB Journal.

[16]  Huazheng Liang,et al.  Genetic polymorphisms in MMP 2, 3, 7, and 9 genes and the susceptibility and clinical outcome of cervical cancer in a Chinese Han population , 2016, Tumor Biology.

[17]  P. Śliwiński,et al.  Matrix metalloproteinase 3 polymorphisms as a potential marker of enhanced susceptibility to lung cancer in chronic obstructive pulmonary disease subjects. , 2014, Annals of agricultural and environmental medicine : AAEM.

[18]  S. Ghanem,et al.  Interleukin 1β and metalloproteinase 3 gene polymorphisms in hepatocellular carcinoma patients in Egypt , 2014 .

[19]  Lin Xu,et al.  Association of Matrix Metalloproteinase-3 -1171(5A>6A) Polymorphism with Cancer Risk: A Meta-Analysis of 41 Studies , 2014, PloS one.

[20]  P. Srivastava,et al.  Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort. , 2013, Gene.

[21]  Guojun Li,et al.  Meta-Analysis of MMP2, MMP3, and MMP9 Promoter Polymorphisms and Head and Neck Cancer Risk , 2013, PloS one.

[22]  S. Swarnakar,et al.  Matrix metalloproteinase3 gene promoter polymorphisms and their haplotypes are associated with gastric cancer risk in eastern Indian population , 2012, Molecular carcinogenesis.

[23]  H. Tamim,et al.  Association of MMP3-1171(5A>6A) polymorphism with lung cancer in Lebanon. , 2012, Genetic testing and molecular biomarkers.

[24]  A. Tardón,et al.  Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival , 2012, BMC Cancer.

[25]  D. Edwards,et al.  Matrix metalloproteinases: protective roles in cancer , 2011, Journal of cellular and molecular medicine.

[26]  D. Christiani,et al.  Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. , 2009, Carcinogenesis.

[27]  F. He,et al.  Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma , 2007, Human mutation.

[28]  M. Nagata,et al.  The 2G allele of promoter region of Matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma , 2007, BMC Cancer.

[29]  J. Kim,et al.  Clinical implications of matrix metalloproteinase‐1, ‐3, ‐7, ‐9, ‐12, and plasminogen activator inhibitor‐1 gene polymorphisms in colorectal cancer , 2007, Journal of gastroenterology and hepatology.

[30]  K. Hemminki,et al.  Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression , 2007, Breast Cancer Research and Treatment.

[31]  D. Boyd,et al.  Regulation of matrix metalloproteinase gene expression , 2007, Journal of cellular physiology.

[32]  Gangqiao Zhou,et al.  Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk , 2007, Gut.

[33]  D. Wakefield,et al.  The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer , 2007, British Journal of Cancer.

[34]  A. Lièvre,et al.  Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma , 2006, BMC Cancer.

[35]  M. Lai,et al.  No Association Between the Polymorphisms in Matrix Metalloproteinase-1 and Matrix Metalloproteinase-3 Promoter Regions and Colorectal Cancer in Chinese , 2006, Diseases of the colon and rectum.

[36]  Xihong Lin,et al.  Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. , 2006, Carcinogenesis.

[37]  W. Guo,et al.  Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. , 2006, Gynecologic oncology.

[38]  S. Kao,et al.  The functional (-1171 5A-->6A) polymorphisms of matrix metalloproteinase 3 gene as a risk factor for oral submucous fibrosis among male areca users. , 2006, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[39]  Y. Hinoda,et al.  Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma. , 2004, Carcinogenesis.

[40]  W. Guo,et al.  The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. , 2004, Carcinogenesis.

[41]  W. Guo,et al.  Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. , 2004, Carcinogenesis.

[42]  Y. Hinoda,et al.  Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. , 2004, Cancer letters.

[43]  M. Oka,et al.  Association of functional polymorphisms of matrix metalloproteinase (MMP)‐1 and MMP‐3 genes with colorectal cancer , 2002, International journal of cancer.

[44]  I. Vořechovský,et al.  Lack of association of the -1171 (5A) allele of the MMP3 promoter with breast cancer. , 2002, Clinical chemistry.

[45]  M. Biondi,et al.  MMP1 and MMP3 polymorphisms in promoter regions and cancer. , 2000, Clinical chemistry.

[46]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[47]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[48]  V. Lesauskaitė,et al.  Matrix Metalloproteinases (MMP-2,-3,-9) Gene Polymorphisms in Cases of Benign Vocal Fold Lesions and Laryngeal Carcinoma , 2019, In Vivo.

[49]  I. Yuasa,et al.  The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. , 2010, Internal medicine.

[50]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.